AR029627A1 - PROTEIN C DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH DERIVATIVES, RECOMBINATING DNA MOLECULES CODING SUCH DERIVATIVES; TRANSFORMATION VECTORS UNDERSTANDING SUCH DERIVATIVES; ISOLATED FROM NUCLEIC ACIDS THAT INCLUDE POLINUCLEOTIDES THAT CODE AT LEAST 90% D - Google Patents

PROTEIN C DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH DERIVATIVES, RECOMBINATING DNA MOLECULES CODING SUCH DERIVATIVES; TRANSFORMATION VECTORS UNDERSTANDING SUCH DERIVATIVES; ISOLATED FROM NUCLEIC ACIDS THAT INCLUDE POLINUCLEOTIDES THAT CODE AT LEAST 90% D

Info

Publication number
AR029627A1
AR029627A1 ARP000101970A ARP000101970A AR029627A1 AR 029627 A1 AR029627 A1 AR 029627A1 AR P000101970 A ARP000101970 A AR P000101970A AR P000101970 A ARP000101970 A AR P000101970A AR 029627 A1 AR029627 A1 AR 029627A1
Authority
AR
Argentina
Prior art keywords
derivatives
protein
polinucleotides
isolated
understanding
Prior art date
Application number
ARP000101970A
Other languages
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR029627A1 publication Critical patent/AR029627A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)

Abstract

Se describen y reivindican nuevos derivados de la proteína C. Se trata de polipéptidos que conservan la actividad biologica de la proteína C humana del tipo silvestre, con semividas en la sangre humana sustancialmente mayor. Estos polipéptidos requerirán una administracion menos frecuente y/o una dosificacion menor que la proteína C humana del tipo silvestre en el tratamiento de trastornos oclusivos vasculares, estados hipercoagulables y enfermedades que predisponen a la trombosis. Específicamente, se trata de derivados de la proteína C humana que comprenden la SEQ ID Ns1. También, se describen y se reivindican los objetos restantes mencionados en el título.New derivatives of protein C are described and claimed. These are polypeptides that retain the biological activity of human wild-type C protein, with substantially higher half-lives in human blood. These polypeptides will require less frequent administration and / or a lower dosage than human wild-type C protein in the treatment of vascular occlusive disorders, hypercoagulable conditions and diseases that predispose to thrombosis. Specifically, these are derivatives of human protein C that comprise SEQ ID Ns1. Also, the remaining objects mentioned in the title are described and claimed.

ARP000101970A 1999-04-30 2000-04-26 PROTEIN C DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH DERIVATIVES, RECOMBINATING DNA MOLECULES CODING SUCH DERIVATIVES; TRANSFORMATION VECTORS UNDERSTANDING SUCH DERIVATIVES; ISOLATED FROM NUCLEIC ACIDS THAT INCLUDE POLINUCLEOTIDES THAT CODE AT LEAST 90% D AR029627A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
AR029627A1 true AR029627A1 (en) 2003-07-10

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101970A AR029627A1 (en) 1999-04-30 2000-04-26 PROTEIN C DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH DERIVATIVES, RECOMBINATING DNA MOLECULES CODING SUCH DERIVATIVES; TRANSFORMATION VECTORS UNDERSTANDING SUCH DERIVATIVES; ISOLATED FROM NUCLEIC ACIDS THAT INCLUDE POLINUCLEOTIDES THAT CODE AT LEAST 90% D

Country Status (11)

Country Link
EP (1) EP1090130A1 (en)
JP (1) JP2002542832A (en)
KR (1) KR20010053345A (en)
AR (1) AR029627A1 (en)
AU (1) AU4188500A (en)
BR (1) BR0006088A (en)
CA (1) CA2338799A1 (en)
HU (1) HUP0102444A3 (en)
IL (1) IL140326A0 (en)
PE (1) PE20010066A1 (en)
WO (1) WO2000066754A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
EP1255821B1 (en) 2000-02-02 2004-12-29 Eli Lilly And Company Protein c derivatives
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
AU2001292308A1 (en) * 2000-09-30 2002-04-15 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hemolytic anemia
EP1328622A2 (en) * 2000-10-18 2003-07-23 Maxygen Aps Protein c or activated protein c-like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2023171719A1 (en) * 2022-03-08 2023-09-14 学校法人自治医科大学 Sequence of activated protein c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69032029T2 (en) * 1989-12-29 1998-08-20 Zymogenetics, Inc., Seattle, Wash. HYBRID PROTEIN C
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
WO1998020118A1 (en) * 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Modified protein c and methods of use thereof

Also Published As

Publication number Publication date
PE20010066A1 (en) 2001-02-02
WO2000066754A1 (en) 2000-11-09
JP2002542832A (en) 2002-12-17
CA2338799A1 (en) 2000-11-09
KR20010053345A (en) 2001-06-25
HUP0102444A3 (en) 2003-09-29
HUP0102444A2 (en) 2001-10-28
IL140326A0 (en) 2002-02-10
AU4188500A (en) 2000-11-17
EP1090130A1 (en) 2001-04-11
BR0006088A (en) 2001-03-20

Similar Documents

Publication Publication Date Title
Legler et al. Chemokines: chemistry, biochemistry and biological function
Ouellette et al. Purification and primary structure of murine cryptdin‐1, a Paneth cell defensin
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
KR970707141A (en) Tumor necrosis factor-gamma
ATE323510T1 (en) GENE THERAPEUTICAL METHODS FOR PROVIDING APOLIPOPROTEIN A-I AGONISTS AND THEIR USE FOR THE TREATMENT OF DYSLIPIDEMIC DISEASES
KR970700438A (en) MACROPHAGE INFLAMMATORY PROTEINS -3, -4 AND -1sg (g)
BR9809914A (en) Lactoferrin receptor moracella genes
DE60127933D1 (en) CHIMERIC PROTEINS AND APPLICATIONS
DK0910647T3 (en) Human DNase in hyperactive variants
CA2067744A1 (en) The human c3b/c4b receptor (cr1)
ATE114169T1 (en) MORPHOGENETIC BONE PROTEIN.
JP2515928B2 (en) High molecular weight human angiogenic factor
AR029627A1 (en) PROTEIN C DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH DERIVATIVES, RECOMBINATING DNA MOLECULES CODING SUCH DERIVATIVES; TRANSFORMATION VECTORS UNDERSTANDING SUCH DERIVATIVES; ISOLATED FROM NUCLEIC ACIDS THAT INCLUDE POLINUCLEOTIDES THAT CODE AT LEAST 90% D
PT1439231E (en) Amino-terminally truncated rantes as chemokine antagonists
ES2124470T3 (en) RECOMBINANT LISTINE OF MISTLETOE.
ATE88500T1 (en) DNA SEQUENCES CODING FOR PROTEINS WITH THE BIOLOGICAL ACTIVITY OF THE HUSI-TYPE INHIBITORS, GENETIC METHODS FOR THE PRODUCTION OF THESE PROTEINS, AND PHARMACEUTICALS CONTAINING THESE PROTEINS.
ATE307886T1 (en) NUCLEOTIDE SEQUENCES, PROTEINS, MEDICATIONS AND DIAGNOSTIC AGENTS FOR USE IN CANCER TREATMENT
BR9911349A (en) Genes for epothilone biosynthesis
DE50010519D1 (en) Pharmaceutical compositions for the treatment of heart failure
HU205617B (en) Process for producing neturophyl-activating factor, gene coding this and pharmaceutical composition
ATE362547T1 (en) POLYMORPHISMS IN THE HUMAN KDR GENES
AR020329A1 (en) A SUBSTANCE, IN PARTICULAR A RIBOZIMA, IS ABLE TO INHIBIT THE PRESENILINE EXPRESSION 2, A RECOMBINATING MOLECULA OF DNA THAT CODIFY SUCH RIBOZIMA, A RECOMBINATING UNVECTOR THAT UNDERSTANDS THE CORRECTING CELL TO A RIBO BELLING ONE.
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
US6121237A (en) Neutrophil stimulating peptides
DE3686786D1 (en) HUMAN PROTEINS OF THE CHINOLINESTERASE TYPE AND THEIR PRODUCTION.